Wells Fargo Maintains Equal-Weight on Halozyme Therapeutics, Raises Price Target to $95
Benzinga Newsdesk 3 months ago
NewsPrice TargetAnalyst Ratings
Wells Fargo analyst Mohit Bansal maintains Halozyme Therapeutics (NASDAQ:HALO) with a Equal-Weight and raises the price target from $75 to $95.
Wells Fargo analyst Mohit Bansal maintains Halozyme Therapeutics (NASDAQ:HALO) with a Equal-Weight and raises the price target from $75 to $95.